Publications
Publications
VANDERGAAST ET AL.
Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus
Molecular Therapy Advances. 2026;34(2):201721.
MUÑOZ-ALÍA ET AL.
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
mBio. 2024. doi: 10.1128/mbio.02928-23
Naik et al.
Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
Mol Cancer Ther. 2018 Jan;17(1):316-326. doi: 10.
Lauro Velazquez-Salinas et al.
Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV
Hum Gene Ther Clin Dev. 2017 Jun 1; 28(2): 108–115.
Zhang et al.
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model
Mol Ther. 2016 Dec; 24(12): 2109–2117.
LeBlanc et al.
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81. doi: 10.1089/humc.2013.165.
Naik et al.
Curative one-shot systemic virotherapy in murine myeloma
Leukemia. 2012 Aug;26(8):1870-8. doi: 10.1038/leu.2012.70. Epub 2012 Mar 19.